Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Inclusion Criteria:

- Subjects with histologically or cytologically confirmed solid tumors, either
refractory to standard therapy or for which no effective standard therapy is
available.

- Measurable or evaluable disease at baseline by RECIST 1.0.

- Age >= 18 years.

- Subject has read and understands the informed consent form and is willing and able to
give informed consent.

- Performance Status score of less than or equal to (<=) 1 according to the Eastern
Cooperative Oncology Group (ECOG) scale.

- Women of childbearing potential must have a negative blood pregnancy test at the
screening visit.

- Female subjects of childbearing potential and male subjects with female partners of
childbearing potential must be willing to avoid pregnancy by using an adequate method
of contraception for 2 weeks prior to screening, during the trial and for 3 months
after the last dose of trial medication.

Additional inclusion criteria also apply.

Exclusion Criteria:

- The subject has previously been treated with mammalian target of rapamycin (mTOR)
inhibitor or a mitogen-activated protein kinase (MEK) inhibitor and taken off
treatment due to drug-related AEs.

- The subject has received any of the following:

- Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, any investigational
agent or any other anti-cancer therapy within 28 days (6 weeks for nitrosoureas or
mitomycin C) of Day 1 of trial treatment; non-cytotoxic chemotherapy or
investigational agent with limited potential for delayed toxicity is permitted if
terminated at least 5 half-lives prior to Day 1 of trial treatment.

- Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone
marrow/stem cell transplantation.

- The subject has not recovered from toxicity due to prior therapy to baseline or CTCAE
v4.0 of Grade 1 or less (except alopecia).

- The subject has poor organ or marrow function as defined in protocol.

- History of central nervous system (CNS) metastases or primary CNS tumor, unless
subject has been previously treated for these conditions, is asymptomatic and has had
no requirement for anticonvulsants or high dose corticosteroids for a minimum of 2
weeks prior to entry into the trial.

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
within 6 months of Day 1 of trial drug treatment.

- Recent major surgery or trauma (within the last 28 days), unhealing/open wounds,
diabetic ulcers, recent drainage of significant volume of ascites or pleural effusion.

- History of congestive heart failure, unstable angina, myocardial infarction,
symptomatic cardiac conduction abnormality, pacemaker, or other clinically significant
cardiac disease or history of a stroke within 3 months prior to entering the trial.

- Baseline corrected QT interval on screening electrocardiogram (ECG) (QTc) >= 460 ms or
left ventricular ejection fraction (LVEF) < 40% on screening echocardiogram.

- Other uncontrolled intercurrent diseases

- Retinal degenerative disease (hereditary retinal degeneration or age-related macular
degeneration), history of uveitis or history of retinal vein occlusion, or medically
relevant abnormal ophthalmology assessments at screening.

- Known or suspected allergy to pimasertib, temsirolimus, other rapamycins (sirolimus,
everolimus, etc.), their excipients, or any agent given in the course of this trial.

- Immunization with attenuated live vaccines within one week of trial entry (examples of
live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG,
etc.).

- Concomitant use of any medications or substances that are strong inhibitors or
inducers of CYP3A enzyme, including, but not limited to, phenytoin, carbamazepine,
barbiturates, azoles, rifampin, phenobarbital, or St. John's Wort.

- Pregnant or lactating female.

- Legal incapacity or limited legal capacity.

Additional exclusion criteria also apply.